Crizotinib

5 mg

Cat. No.: 61-V83

$129.00

Crizotinib is a potent ATP competitive inhibitor of c-MET and anaplastic lymphoma kinase (ALK). It has been shown to display antitumor efficacy in multiple tumor models and has been shown to inhibit c-MET dependent proliferation, migration and invasion of tumor cells in vitro. Crizotinib is selective for c-MET and ALK against over 120 different kinases. 

Categories: ,

Details

TECHNICAL INFORMATION

Other Names: PF-02341066, PF-1066, PF-2341066

Chemical Formula:  C21H22Cl2FN5O

CAS Number: 877399-52-5

Molecular Weight: 450.34

Purity:  >98%

Appearance:  a crystalline solid  

Solubility: DMSO

 

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store  aliquots at -20°C. 

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

 

PRODUCT USE

Soluble in DMSO at 25 mg/ml. If precipitate is observed,  vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

References

Cui et al. (2011) Structure based drug design of crizotinib (PF-02341066) | a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 54(18):6342-63.

Rodig et al. (2010) Crizotinib | a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 11(12):1477-90.

Gerber et al. (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 18(6):548-51.

Tech Docs

Product Specifications

MSDS

Related products